老年病人血清Aβ42与磷酸化Tau蛋白检测的临床价值

doi:10.3969/j.issn.1003-9198.2022.12.011

Abstract

Abstract: Objective To investigate the clinical value of serum amyloid-beta 42(Aβ42) and phosphorylated Tau (p-Tau). Methods A total of 425 elderly cases were enrolled in this study who received the measurement of Aβ42 and p-Tau at the same time. The positive rate of Aβ42 and p-Tau was analyzed in the elderly patients with dementia or other diseases. Results The overall positive rate of serum Aβ42 and p-Tau was 36.2% and 24.7% respectively, and 21.4% of the patients presented with both positive Aβ42 and p-Tau. Among the patients diagnosed as cognitive impairment, dementia and AD, the positive rate of Aβ42was 23.8%, 44.9%, 50.0% respectively, and the positive rate of p-Tau was 12.4%, 22.4%, 16.7% respectively. However, both of them were positive in 64.7% of the patients with pulmonary infection or inflammation diseases, and they were almost positive simultaneously in a patient. Conclusions The diagnostic values of serum Aβ42 and p-Tau for AD might be limited, but they might be potential indicators of pulmonary infection or inflammation disorders.

Key words: Alzheimer's disease, dementia, cognitive disorder, serum amyloid-beta 42, serum phosphorylated Tau

CLC Number:

R749.16

ZHENG Qian, TAO Yue, CHEN Yi-qiang, LIU Si-yuan, CHEN De-zhu, PENG Lu, GU Shou-yong, CAI Min-qi, BAI Bing. Clinical value of serum amyloid-beta 42 and phosphorylated Tau in elderly patients[J]. Practical Geriatrics, 2022, 36(12): 1229-1232.

References

[1] JACK C R Jr., BENNETT D A, BLENNOW K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease [J]. Alzheimers Dement, 2018, 14(4): 535-562.
[2] LONG J M, HOLTZMAN D M. Alzheimer disease: an update on pathobiology and treatment strategies [J]. Cell, 2019, 179(2): 312-339.
[3] OLSSON B, LAUTNER R, ANDREASSON U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis [J]. Lancet Neurol, 2016, 15(7): 673-684.
[4] 陈心怡,孙杨,徐德恩. 阿尔茨海默病外周血液生物标志物的研究进展 [J]. 实用老年医学, 2021, 35(10): 1076-1079.
[5] 尹倩然,郝敬波,卢海龙,等. 血p-Tau181、Aβ1-42与老年阿尔茨海默病病人认知关系的研究 [J]. 实用老年医学, 2021, 35(6): 741-743.
[6] 黄海华,李明秋,丘江,等. 阿尔茨海默病患者睡眠障碍与血清β-淀粉样蛋白1-42、磷酸化tau蛋白181的相关性研究 [J]. 中华老年医学杂志, 2021, 40(4): 438-443.
[7] MEHTA P D, PIRTTILA T, MEHTA S P, et al. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease [J]. Arch Neurol, 2000, 57(1): 100-105.
[8] MOTTER R, VIGO-PELFREY C, KHOLODENKO D, et al. Reduction of beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease [J]. Ann Neurol, 1995, 38(4): 643-648.
[9] TEUNISSEN C E, CHIU M J, YANG C C, et al. Plasma amyloid-β (Aβ42) correlates with cerebrospinal fluid Aβ42 in Alzheimer's disease [J]. J Alzheimers Dis, 2018, 62(4): 1857-1863.
[10] LUE L F, SABBAGH M N, CHIU M J, et al. Plasma levels of Aβ42 and Tau identified probable Alzheimer's dementia: Findings in two cohorts [J]. Front Aging Neurosci, 2017, 9: 226.
[11] RISACHER S L, FANDOS N, ROMERO J, et al. Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition [J]. Alzheimers Dement (Amst), 2019, 11: 510-519.
[12] PALMQVIST S, JANELIDZE S, STOMRUD E, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status [J]. JAMA Neurol, 2019, 76(9): 1060-1069.
[13] SHI Y, LU X, ZHANG L, et al. Potential value of plasma amyloid-beta, total tau, and neurofilament light for identification of early Alzheimer's disease [J]. ACS Chem Neurosci, 2019, 10(8): 3479-3485.
[14] BAI B, WANG X, LI Y, et al. Deep multilayer brain proteomics identifies molecular networks in Alzheimer's disease progression [J]. Neuron, 2020, 105(4): 700.
[15] KUKULL W A, BRENNER D E, SPECK C E, et al. Causes of death associated with Alzheimer disease: variation by level of cognitive impairment before death [J]. J Am Geriatr Soc, 1994, 42(7): 723-726.
[16] GANGULI M, DODGE H H, SHEN C, et al. Alzheimer disease and mortality: a 15-year epidemiological study [J]. Arch Neurol, 2005, 62(5): 779-784.
[17] WILHELM M, SCHLEGL J, HAHNE H, et al. Mass-spectrometry-based draft of the human proteome [J]. Nature, 2014, 509(7502): 582-587.
[18] KIM M S, PINTO S M, GETNET D, et al. A draft map of the human proteome [J]. Nature, 2014, 509(7502): 575-581.
[19] KINNEY J W, BEMILLER S M, MURTISHAW A S, et al. Inflammation as a central mechanism in Alzheimer's disease [J]. Alzheimers Dement: N Y, 2018, 4: 575-590.
[20] WALKER K A, FICEK B N, WESTBROOK R. Understanding the role of systemic inflammation in Alzheimer's disease [J]. ACS Chem Neurosci, 2019, 10(8): 3340-3342.
[21] WOOD H. Dementia: peripheral inflammation could be a prodromal indicator of dementia [J]. Nat Rev Neurol, 2018, 14(3): 127.
[22] MCMANUS R M, HIGGINS S C, MILLS K H, et al. Respiratory infection promotes T cell infiltration and amyloid-beta deposition in APP/PS1 mice [J]. Neurobiol Aging, 2014, 35(1): 109-121.
[23] LITTLE C S, HAMMOND C J, MACINTYRE A, et al. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice [J]. Neurobiol Aging, 2004, 25(4): 419-429.
[24] EIMER W A, VIJAYA KUMAR D K, NAVALPUR SHANMUGAM N K, et al. Alzheimer's disease-associated beta-amyloid is rapidly seeded by herpesviridae to protect against brain infection [J]. Neuron, 2018, 99(1): 56-63.e3.
[25] KUMAR D K, CHOI S H, WASHICOSKY K J, et al. Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer's disease [J]. Sci Transl Med, 2016, 8(340): 340ra72.
[26] FULOP T, WITKOWSKI J M, BOURGADE K, et al. Can an infection hypothesis explain the beta amyloid hypothesis of Alzheimer's disease? [J]. Front Aging Neurosci, 2018, 10: 224.
[27] SY M, KITAZAWA M, MEDEIROS R, et al. Inflammation induced by infection potentiates tau pathological features in transgenic mice [J]. Am J Pathol, 2011, 178(6): 2811-2822.
[28] WOZNIAK M A, FROST A L, ITZHAKI R F. Alzheimer's disease-specific tau phosphorylation is induced by herpes simplex virus type 1 [J]. J Alzheimers Dis, 2009, 16(2): 341-350.

Clinical value of serum amyloid-beta 42 and phosphorylated Tau in elderly patients

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 5

Metrics

Recommended 10

[1]	LIU Li-juan, JIANG Man, CHENG Yong, MAO Gao-feng, FANG Huang. Relationship of serum levels of AGEs and RAGE with dementia severity in elderly patients with vascular dementia after cerebral infarction [J]. Practical Geriatrics, 2023, 37(8): 853-857.
[2]	MA Zong-juan, LUO Chang-chun, DENG Bao-feng, WANG Hui-min, HU Yue-qing. Comprehensive geriatric assessment status and coping strategies for patients with dementia complicated with COVID-19 [J]. Practical Geriatrics, 2023, 37(12): 1189-1192.
[3]	DU Hong-di, BO Lin, YIN Li-sha, LUO Dan-dan, HUO Xiao-peng. Effect of simulated presence therapy on apathy in patients with mild and moderate dementia [J]. Practical Geriatrics, 2022, 36(10): 1071-1074.
[4]	HUANG Xin-yi, HAN Yue, GENG Gui-ling, GU Ting. Reliability and validity of the Chinese version of the Rowland Universal Dementia Assessment Scale [J]. Practical Geriatrics, 2021, 35(7): 668-672.
[5]	GUO Ming-Xian, GUO Feng, GAO Li, ZHANG Gui-Gong, ZHANG Xiu-Fen, LV Shu-Ping. Epidemiological survey and analysis about senile dementia among the elderly living in groups in Xi'an [J]. Practical Geriatrics, 2010, 24(2): 125-127.